With the accelerated pace of life in modern society, the prevalence of type 2 diabetes mellitus in overweight or obese people is increasing year by year, thus increasing the risk of cardiovascular disease.[1] Glucagon like peptide-1 (GLP-1) receptor agonist can reduce glucose in a glucose concentration dependent manner by simulating the activation of natural GLP-1 receptor, while simultaneously reducing weight, lowering blood pressure, and improving blood lipid profile.[2] As a new hypoglycemic drug, GLP-1 receptor agonist is currently receiving more and more clinical attention. This evidence concerns the gene GLP1R and diabetes mellitus.